GLYCOGENE
Your trusted partner for Nucleic Acid and Carbohydrate raw materials
GLYCOGENE
Products
GLYCOGENE
Service
WHO ARE WE？
About GLYCOGENE
Founded in 2019 by experts in nucleic acids, glycoscience, and enzyme evolution, Glycogene Inc. brings together a leadership team of U.S.-trained scientists with over 20 years of experience in research, biotechnology, and commercialization. The company is headquartered in Wuhan, with a U.S. subsidiary in North Carolina, and is supported by R&D centers and pilot-scale laboratories in Qingdao and Shenzhen, as well as manufacturing facilities in Panjin.
With 250+ employees, Glycogene operates a proprietary chemo-enzymatic synthesis platform that integrates advanced technologies in nucleic acid and glycan engineering. We are committed to providing high-quality, cost-effective products and services to accelerate global innovation in nucleic acid and glycan-related development.
Technologies breakthrough in RNA field
2006: Nobel Prize for RNA Interference (RNAi) Mechanism Laid the Theoretical Foundation for Oligonucleotide Drugs
2006: Nobel Prize for RNA Interference (RNAi) Mechanism Laid the Theoretical Foundation for Oligonucleotide Drugs
2005-2010: Elucidation of Nucleobase Modification and Immune Interaction Resolved the Early Severe Immunotoxicity of Exogenous mRNA
2005-2010: Elucidation of Nucleobase Modification and Immune Interaction Resolved the Early Severe Immunotoxicity of Exogenous mRNA
2014: Birth of GalNAc Liver-Targeted Delivery Technology — A Breakthrough for Oligonucleotide Industrialization
2014: Birth of GalNAc Liver-Targeted Delivery Technology — A Breakthrough for Oligonucleotide Industrialization
2018: Global First siRNA Drug Onpattro Approved — Nucleic Acid Drugs Officially Enter Commercialization
2018: Global First siRNA Drug Onpattro Approved — Nucleic Acid Drugs Officially Enter Commercialization
2020: Global Emergency Approval of mRNA COVID-19 Vaccines — Nucleic Acid Technology Achieved Mass Popularization
2020: Global Emergency Approval of mRNA COVID-19 Vaccines — Nucleic Acid Technology Achieved Mass Popularization
2021 Inclisiran: A Landmark Success in RNAi Therapeutics for Chronic Disease
2021 Inclisiran: A Landmark Success in RNAi Therapeutics for Chronic Disease
Technologies breakthrough in glycoscience field
Blog Center
Working Together, Chasing the Light | Tangzhi Pharmaceutical 2025 New Year Gala
As the year turns and a new chapter unfolds, we look back on 2024, a year of progress and achievement for Tangzhi. This year, we held grand annual meetings in Wuhan, Qingdao, and Panjin, celebrating our successes together. Wuhan, as the headquarters of Tangzhi Pharmaceutical, holds our initial aspirations and dreams. In 2024, we achieved remarkable results. The company was successfully selected for Wuhan's "Backbone High-tech Enterprise Gazelle Plan" and recognized as a "Potential Unicorn" enterprise in the East Lake High-tech Development Zone, a "2024 Deloitte China High-Tech High-Growth 50 Strong" company, and a "2024 Deloitte Guanggu High-Tech High-Growth Top 20" company. Over the past year, Tangzhi Pharmaceutical has continued to focus on technological innovation and product development, resulting in steady revenue growth. At the Wuhan annual meeting, in his opening address, Chairman Wang Peng reviewed the outstanding achievements we made in technological innovation and market expansion, thanked every employee for their hard work, and looked forward to the new year, where we will continue to cultivate the fields of sugar and nucleic acids, providing even better products and services to global customers.
2025-01-27
Recently, the "2024 Deloitte China Technology Fast 50" (hereinafter referred to as "China 50") was announced. Tangzhi Pharmaceutical, with its outstanding performance and rapid growth in the fields of sugar and nucleic acids, was honored to be on the list, ranking 15th with a revenue growth rate exceeding 690%! This honor is not only an affirmation of Tangzhi Pharmaceutical's innovative strength in the fields of sugar and nucleic acids, but also a commendation for its high-speed growth in a difficult environment. The Deloitte China Technology Fast 50 program has always been regarded as a "benchmark for high-growth companies globally." The selection of Tangzhi Pharmaceutical marks its leading position and strong competitiveness in the industry.
2025-01-21
New DNA-encoded chemical library technology to aid drug discovery and development
(Science and Technology Daily) Although researchers have made significant progress in the development of molecular therapies in recent years, the number of newly discovered active substances remains insufficient. Now, the DNA-encoded chemical library (DEL) technology, jointly developed by Harvard University in the US and ETH Zurich in Switzerland, offers a new solution. The technology can automate the synthesis and testing of billions of compounds in a matter of weeks, and can also be used to produce larger drug molecules that will act on targets that are difficult to reach with traditional small molecules.
2024-09-25
